Ennature Biopharma, a natural ingredients platform, reported revenue of INR 246 Cr and EBITDA of INR 29 Cr for its recent fiscal year.

The Plant-based API segment is the largest, contributing 67% of sales and providing stable cash flow, while Nutraceuticals (17%) and Biopolymers (16%) are key growth areas.

The core strategy involves leveraging the stable API business to fuel expansion in high-value branded Nutraceuticals.

This includes broadening the branded nutraceutical portfolio with 2-3 new products and establishing a local US office for better market reach.

Management sees Nutraceuticals as the primary growth driver, planning to scale to 6-8 branded ingredients and expand global distribution.

The API segment will focus on introducing one new product annually and expanding into new geographies.

Biopolymers aim for a higher-value product mix, particularly in dietary-fibre and food ingredients.